Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors

Avanir Pharmaceuticals, Inc.

today announced the appointment of Dr. Mark Corrigan to the company's board of directors. Dr. Corrigan, a seasoned life sciences executive joins Avanir's board with broad healthcare industry experience. Dr. Corrigan currently serves as president and chief executive officer of Zalicus Inc. a public biopharmaceutical company, a position he has held since January 2010. He has also served as a director of Zalicus and its progenitor companies since December 2006. Prior to Zalicus, Dr. Corrigan served as executive vice president, research and development at Sepracor, Inc. (now known as Sunovion Pharmaceuticals, Inc.). Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, a pharmaceutical company acquired by Pfizer, Inc. in 2003, most recently as group vice president of Global Clinical Research and Experimental Medicine. Prior to joining the pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan has also been a member of the board of directors and audit committee of Cubist Pharmaceuticals, Inc. since June 2008. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and subsequently received specialty training in Psychiatry at Cornell and Maine Medical Center. "It is a pleasure to welcome Mark to the Avanir Board," commented Craig Wheeler, chairman of the board, "Mark brings many years of experience in the healthcare sector combined with a deep knowledge of CNS research and development together with broad experience in guiding the growth of biopharma companies. I look forward to the insights he will bring to our board and to working with him as Avanir pursues its growth initiatives." About Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com. AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries. ©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.